Platelet aggregation pathway

Sangkuhl, Katrin; Shuldiner, Alan R.; Klein, Teri E.; Altman, Russ B.

doi:10.1097/fpc.0b013e3283406323

Cited by 105 publications

(87 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The network was constructed by using the information retrieved from five published literatures [15–19], Reactome [20], and KEGG [21]. The enzymes which participated in the pathway were proposed as nodes, and arrows between nodes represented the connections.…”

Section: Methodsmentioning

confidence: 99%

Platelet Aggregation Pathway Network-Based Approach for Evaluating Compounds Efficacy

Chen

et al. 2013

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Traditional Chinese medicines (TCMs) contain a large quantity of compounds with multiple biological activities. By using multitargets docking and network analysis in the context of pathway network of platelet aggregation, we proposed network efficiency and network flux model to screen molecules which can be used as drugs for antiplatelet aggregation. Compared with traditional single-target screening methods, network efficiency and network flux take into account the influences which compounds exert on the whole pathway network. The activities of antiplatelet aggregation of 19 active ingredients separated from TCM and 14 nonglycoside compounds predicated from network efficiency and network flux model show good agreement with experimental results (correlation coefficient = 0.73 and 0.90, resp.). This model can be used to evaluate the potential bioactive compounds and thus bridges the gap between computation and clinical indicator.

show abstract

Section: Methodsmentioning

confidence: 99%

Platelet Aggregation Pathway Network-Based Approach for Evaluating Compounds Efficacy

Chen

et al. 2013

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…PLA2 activation releases AA, a TBXA2 precursor, with prostaglandin G/H synthase 1 catalyzing the first step in the formation of TBXA2 from AA. These processes result in the local accumulation of molecules such as thrombin, TXA2 and ADP, which are important for further platelet aggregation (20). The results of the TXA2 assay conducted in the present study indicate that this reaction was blocked by synthetic polyphosphate, thereby reducing platelet aggregation.…”

Section: Discussionmentioning

confidence: 54%

“…Different quantities (20,40 and 80 µl) of polyphosphate were added to 3 ml whole blood in a citrated tube, and all TEG analyses were performed with a kaolin and CaCl 2 active assay kit and TEG instrument (CFMS™; Lepu Medical Technology Co., Ltd., Beijing, China) (9). All experiments were performed in triplicate, and 250 mM LiCl was used as a control treatment.…”

Section: Methodsmentioning

confidence: 99%

Synthetic polyphosphate inhibits endogenous coagulation and platelet aggregation in vitro

et al. 2016

View full text Add to dashboard Cite

Abstract. Platelet-derived polyphosphate has previously been indicated to induce coagulation. However, industrially synthesized polyphosphate has been found to have different effects from those of the platelet-derived form. The present study investigated whether synthetic sodium polyphosphate inhibits coagulation using routine coagulation tests and thromboelastography. Synthetic polyphosphate was found to inhibit adenosine diphosphate-, epinephrine-, arachidonic acid-, ristocetin-, thrombin-, oxytocin-and pituitrin-induced platelet aggregation. The effects of synthetic polyphosphate in clotting inhibition were revealed by the analysis of clotting factor activity and platelet aggregation tests. Synthetic polyphosphate may inhibit platelet aggregation by reducing platelet calcium levels, as indicated by the results of flow cytometric analysis and high-throughput fluorescent screening. Furthermore, analysis of thromboxane (TX) B2 by ELISA indicated that synthetic polyphosphate reduces platelet aggregation by inhibiting the TXA2 signaling pathway. In conclusion, synthetic polyphosphate inhibits clotting factor activity and endogenous coagulation by reducing the levels of calcium ions and TXA2 to curb platelet aggregation.

show abstract

“…3 as an example. We currently have 99 curated pathways [April 2013], many of which have been published in peer reviewed journals [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35].…”

Section: Pathwaysmentioning

confidence: 99%